Exhibit 16.1
[GRANT THORNTON LETTERHEAD]
March 31, 2006
U.S. Securities and Exchange Commission
Office of the Chief Accountant
100 F Street, NE
Washington, DC 20549
Re: | Savient Pharmaceuticals, Inc. File No. 0-15313 |
Dear Chief Accountant:
We have read Item 4.01 of Form 8-K of Savient Pharmaceuticals, Inc. dated March 28, 2006 and agree with the statements concerning our Firm contained therein.
Very truly yours,
/s/ Grant Thornton LLP
[GRANT THORNTON LETTERHEAD]
March 31, 2006
Mr. Stephen O. Jaeger
Chairman Audit and Finance Committee
Savient Pharmaceuticals, Inc
One Tower Center
East Brunswick, New Jersey 08816
Dear Mr. Jaeger:
This is to confirm that the client-auditor relationship between Savient Pharmaceuticals, Inc. (U.S. Securities and Exchange Commission File No. 0-15313) and Grant Thronton LLP has ceased.
Very truly yours,
/s/ Grant Thornton LLP
cc: | Office of the Chief Accountant PCAOB Letter File U.S. Securities and Exchange Commission 100 F Street, NE Washington, DC 20549 |